Evotec stock falls to a new 52-week low as analysts split on 2026 outlook

Published on 09/14/2026 at 14:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock dropped to a new 52-week low on Xetra on September 14, 2026, while analysts now see 2026 revenue between EUR 570 million and EUR 610 million. Diverging price targets from Deutsche Bank and RBC highlight the uncertainty around the turnaround.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) came under renewed pressure on Xetra on September 14, 2026, with the shares sliding to a fresh 52-week low of EUR 2.86 in intraday trading and extending a sharp year-to-date loss of 44 percent reported for 2026. According to Trading-Treff on September 14, 2026, the company now expects revenue between EUR 570 million and EUR 610 million for 2026, reflecting a more cautious outlook.

Evotec stock hits 52-week low on Xetra

As finanzen.ch reported on September 14, 2026, Evotec SE shares fell by 2.4 percent to EUR 2.90 in Xetra trading around 12:28 p.m., after opening at EUR 2.95 and touching an intraday low of EUR 2.86. The same report highlighted that EUR 2.86 marked the current 52-week low, underscoring how the stock has slid from earlier levels and now trades only a small distance above that low at midday. Earlier in the morning session, finanzen.ch noted a quote of EUR 2.96 at 9:28 a.m., down 0.3 percent on the day and already testing the lower end of the recent range.

For context, a separate price snapshot showed Evotec stock at EUR 2.982 at the close of Xetra trading on September 11, 2026, down 2.5 percent from the prior session and with an intraday range between EUR 2.918 and EUR 3.090. That same snapshot stated that the shares lost 7.6 percent between September 4, 2026 and September 11, 2026, indicating that the move to EUR 2.90 on September 14, 2026 extends a multi-session downtrend rather than a single-day fluctuation. The fresh 52-week low at EUR 2.86 therefore sits clearly below the prior week low of EUR 2.918 and signals ongoing selling pressure.

Guidance cut and divergent analyst targets

The fundamental backdrop for Evotec has shifted in recent weeks, with management now working against lower guidance for the current year. According to Trading-Treff on September 14, 2026, the company expects 2026 revenue only between EUR 570 million and EUR 610 million, a corridor that reflects a more conservative view of its order and project pipeline. Analysts cited by the same article forecast a loss of EUR 1.297 per share for the 2026 financial year, pointing to a year in which profitability remains under pressure despite ongoing restructuring efforts.

The analyst community appears split on how to value Evotec stock in light of the lower guidance and expected loss. As Trading-Treff reported, RBC Capital Markets in September 2026 confirmed a price target of EUR 10.00 for Evotec shares, which implies substantial upside from the Xetra level around EUR 2.90. In contrast, Deutsche Bank set a markedly lower price target of EUR 3.50 in September 2026, only slightly above the current market price and close to the new 52-week low; this EUR 3.50 target sits 65.0 percent below the RBC target and highlights the wide divergence in views on Evotec’s turnaround potential.

The same analyst overview noted that the range of current price targets spans from EUR 3.50 to EUR 10.00, underscoring the uncertainty around Evotec’s 2026 revenue path and the effectiveness of its restructuring and cost-saving measures. With the shares finishing a recent session at EUR 3.03, only 1.9 percent above a previous 52-week low of EUR 2.97 referenced in the article, the stock is trading far below the optimistic EUR 10.00 target and still below the midpoint of the company’s guided 2026 revenue corridor. For investors, the quantified gap between the current price near EUR 2.90 and the analyst range from EUR 3.50 to EUR 10.00 is now a central part of the risk-reward discussion.

Loss expectations and investor perspective

Beyond revenue guidance and price targets, expectations for the bottom line remain subdued. According to projections highlighted by finanzen.ch on September 14, 2026, experts estimate that Evotec SE will post a loss of EUR 1.297 per share in its 2026 financial statements. This expected loss contrasts with the company’s longer-term ambition to return to profitable growth and suggests that the current year is still dominated by restructuring costs and operational challenges rather than margin expansion.

The combination of a guided 2026 revenue corridor of EUR 570 million to EUR 610 million and an anticipated loss per share of EUR 1.297 means the market is assessing Evotec on its ability to stabilize operations rather than on immediate earnings delivery. With the share price at EUR 2.90 as of around 12:28 p.m. on September 14, 2026, roughly 1.4 percent above the fresh 52-week low of EUR 2.86 and far below the EUR 10.00 upper analyst target, the implied price-to-sales ratio for the midpoint of the revenue guidance remains modest. However, the near-term loss expectation limits support from valuation metrics based on earnings, which helps explain why Deutsche Bank’s EUR 3.50 target sits only marginally above the current price level.

Evotec stock near its low in the MDAX

In the midday Xetra session on September 14, 2026, finanzen.ch placed Evotec among the underperformers in the MDAX, noting that the index stood around 31,187 points while Evotec’s shares dropped 2.4 percent to EUR 2.90. Volume in Evotec reached 295,341 shares at that point, indicating active trading as the stock probed new lows. For investors, the technical picture is now dominated by the 52-week low at EUR 2.86 and the narrow band between that low and the most recent closing prices around EUR 2.982, a range that illustrates how little buffer remains above the yearly trough.

Should Evotec deliver revenue closer to the upper end of the EUR 570 million to EUR 610 million corridor in 2026 while containing the projected loss of EUR 1.297 per share, the wide analyst target span from EUR 3.50 to EUR 10.00 suggests that the stock could see meaningful repricing. Until then, however, the share price hovering near the 52-week low indicates that the market is waiting for clearer evidence of operational improvement. For investors following Evotec stock, the quantified guidance corridor, the expected loss, and the stark contrast between Deutsche Bank’s EUR 3.50 target and RBC’s EUR 10.00 target frame the current debate.

Evotec stock price snapshot

Evotec stock is referenced to Xetra as its primary trading venue. As of September 14, 2026 around 12:28 p.m., the shares traded at EUR 2.90 after opening at EUR 2.95, with an intraday low of EUR 2.86 and an earlier quote of EUR 2.96 at 9:28 a.m. The latest completed close at EUR 2.982 on September 11, 2026 represented a 2.5 percent decline from the prior session and formed part of a 7.6 percent drop between September 4, 2026 and September 11, 2026. Against a 52-week low of EUR 2.86 recorded on September 14, 2026 and prior lows around EUR 2.97 referenced in analyst commentary, the current price level underscores how Evotec stock remains pinned near the bottom of its one-year range.